Veeva Announces Alliances for Digital Field Engagement
Veeva Systems (NYSE:VEEV) today announced industry alliances to accelerate the industrywide shift toward digital engagement. Together with Accenture, Deloitte, and other alliance partners, Veeva is helping life sciences companies design and implement new digital engagement strategies. The Digital Field Engagement offering will help the industry leverage digital channels such as remote meetings, virtual events, and email as the primary way for field reps to connect with healthcare professionals (HCPs).
“We are coming together to help life sciences accelerate its digital transformation through a combination of strategic services, modern cloud applications, and rapid implementation support,” said Dan Rizzo, vice president of global business consulting at Veeva. “Biopharmaceutical companies will be able to quickly shift their customer engagement strategies to digital as in-person access declines.”
Veeva’s Digital Field Engagement solution provides a roadmap for customers to connect with HCPs using digital channels. In the four-week engagement, Veeva defines the roles, responsibilities, tools, data, and training needed for digital engagement. Customers get best practices for remote detailing and remote sampling using Veeva CRM Engage Meeting and sending compliant content with Veeva CRM Approved Email, as well as a complete roadmap for the processes and technologies to implement.
Accenture, Deloitte, and other partners will support the execution of the digital engagement strategy. Together, Veeva and its ecosystem of partners are helping life sciences customers implement business process change and get up and running fast.
Read expert advice and best practices from Veeva to help you engage better via digital channels here.
Learn how Veeva is helping customers leverage digital to connect with HCPs at the upcoming Veeva Summit on June 9, 2020. Pre-register for the virtual event and stay up-to-date on program details at veeva.com/Summit.
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc. Veeva Systems Inc. owns other registered and unregistered trademarks.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 13:30:00 CEST | Press release
The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na
TIP Trailer Services Announces Appointment of New CFO25.5.2020 10:05:00 CEST | Press release
TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY ® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 08:00:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio
JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 08:00:00 CEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine
U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer22.5.2020 22:30:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations. “We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with brain metastases,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “Through a robust clinical development program and ongoing investigations across the NSCLC treatment landscape, Takeda is committed to uncovering solutions for people living with devastating forms of lung cancer in need of new options. We believe this approva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom